Access Vascular Raises $22M in Series C

Access Vascular, a Billerica, MA-based company addressing the vascular access complications via a biomaterial platform, raised $22M in Series C funding.

Backers included a consortium of new and existing investors.

The company intends to use the funds for:

  • substantial production capacity increase of MIMIX™ hydrophilic biomaterial vascular access devices,
  • further research into the potential for MIMIX to lower catheter infection rates, and
  • expansion of product portfolio.

Led by James Biggin, Founder and CEO, Access Vascular was founded to address the common complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a different approach to thrombus reduction, the company manufactures intravenous catheters from a proprietary hydrophilic material. Engineered to mimic the body’s natural chemistry, its catheters are designed to evade the foreign body response and the complications that come with it. Its FDA-cleared products are HydroPICC® and HydroMID®.